XLRN up +2.88% percent right now. $XLRN High is at 33.24 and the Low 31.01 with current volume of 87,058.
Recent News posted below.
XLRN Acceleron Pharma Inc Recent Headline News
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.70 (+0.08), CRIS: 1.31 (-0.02), IMMU: 3.71 (-0.01), PCYC: 134.58 (+0.60), ONCY: 0.84 (unch), PFE: 30.23 (+0.03), LLY: 67.95 (-0.40), BMY: 58.71 (-0.10), GSK: 45.82 (+0.66), JNJ: 108.86 (+0.04), SNTA: 3.34 (+0.23), NVS: 92.66 (+0.03), XLRN: 33.39 (+1.13), ARRY: 3.90 (+0.06), CELGZ: 3.19 (-0.02), EXEL: 1.80 (+0.01)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.22 (-0.17), LLY: 67.95 (-0.40), CNCE: 13.24 (-0.13), OPK: 8.50 (-0.13), AZN: 74.27 (+1.06), ALXN: 194.99 (-0.81), ICPT: 171.32 (-5.03), NPSP: 29.33 (+2.42), XLRN: 33.39 (+1.13)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.01), IMGN: 9.97 (+0.02), AMGN: 162.38 (-0.71), LLY: 67.95 (-0.40), ONTX: 4.90 (+0.04), BMY: 58.71 (-0.10), GSK: 45.82 (+0.66), OXGN: 1.90 (-0.08), XLRN: 33.39 (+1.13), KPTI: 42.50 (-0.18), NVS: 92.66 (+0.03)
Acceleron Pharma's (XLRN) CEO John Knopf on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:29AM CST
XLRN: 33.39 (+1.13)
Acceleron posts 3Q loss
Automated Insights - Fri Nov 07, 7:15AM CST
CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Friday reported a loss of $8 million, or 25 cents per share, in its third quarter.
XLRN: 33.39 (+1.13)
Acceleron Pharma beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:32AM CST
XLRN: 33.39 (+1.13)
Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results
Business Wire - Fri Nov 07, 6:30AM CST
--- Phase 2 data from end-stage renal disease trial to be presented at ASN -
XLRN: 33.39 (+1.13)
Acceleron Announces New Clinical Data Presentations at the 2014 American Society of Hematology Annual Meeting
Business Wire - Thu Nov 06, 8:32AM CST
--Phase 2 data from myelodysplastic syndromes trial selected for oral presentation
XLRN: 33.39 (+1.13)
Acceleron Pharma Is Due For A Market Correction And Is An Attractive Short Candidate During The Coming Months
Clinically Sound Investor - at Seeking Alpha - Fri Oct 31, 7:59AM CDT
XLRN: 33.39 (+1.13)
Acceleron Pharma to Host Third Quarter 2014 Financial Results Conference Call and Webcast on November 7, 2014
Business Wire - Thu Oct 30, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio webcast to report its third quarter 2014 financial results and provide a corporate update on Friday, November 7, 2014, at 9:00 AM EST.
XLRN: 33.39 (+1.13)
Acceleron Pharma to Present at Upcoming Investor Conferences in November
Business Wire - Wed Oct 29, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in several upcoming investor conferences.
XLRN: 33.39 (+1.13)
Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014
Business Wire - Thu Oct 23, 9:52AM CDT
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that its collaboration partner, Celgene, and investigators on the sotatercept program will present preclinical and interim clinical data at the American Society of Nephrology (ASN) Kidney Week 2014. The meeting will be held in Philadelphia on November 11-16, 2014.
XLRN: 33.39 (+1.13)
Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder
Business Wire - Wed Oct 22, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder (CKD-MBD) with Ravi Thadhani, M.D., M.P.H. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept in patients with end-stage renal disease with mineral and bone disorder.
XLRN: 33.39 (+1.13)
A Quick Look at Celgene Corporation's Drug Development Pipeline
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 16, 8:35AM CDT
Source: Dr. Wendy Longo via Flickr . We're taught, as investors, to keep our eyes on the future because the stock market rarely gives much credence to what a business has done in the past. This couldn't be truer when it comes to the...
XLRN: 33.39 (+1.13), CELG: 107.50 (-0.51)
Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083
Business Wire - Tue Oct 14, 6:30AM CDT
-- Fourth internally discovered drug expands Acceleron's clinical pipeline --
XLRN: 33.39 (+1.13)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 86.29 (-1.31), ARQL: 1.19 (+0.02), BMY: 58.71 (-0.10), GSK: 45.82 (+0.66), ONTY: 1.68 (+0.01), ECYT: 6.41 (+0.23), MRK: 59.39 (+0.58), AEZS: 0.61 (-0.01), GALE: 1.94 (+0.01), NVS: 92.63 (unch), XLRN: 33.39 (+1.13), KPTI: 42.50 (-0.18)
Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline
at The Street - Thu Oct 02, 8:21AM CDT
An Acceleron update in December could reignite investor interest in the stock.
BLUE: 42.00 (-0.50), XLRN: 33.39 (+1.13)
Will Acceleron (XLRN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 7:56AM CDT
Will Acceleron (XLRN) Continue to Surge Higher?
XLRN: 33.39 (+1.13)
Acceleron to Host Educational Webcast on Beta-thalassemia
Business Wire - Wed Oct 01, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on beta-thalassemia with Ellis Neufeld, M.D., Ph.D. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept and luspatercept in patients with beta-thalassemia, MDS, and end-stage renal disease with mineral and bone disorder.
XLRN: 33.39 (+1.13)
Acceleron to Webcast Presentation at Leerink Partners Rare Disease Roundtable
Business Wire - Mon Sep 29, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will present a corporate overview at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 10:15 a.m. EDT at Le Parker Meridien Hotel in New York City.
XLRN: 33.39 (+1.13)
Recent News posted below.
XLRN Acceleron Pharma Inc Recent Headline News
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.70 (+0.08), CRIS: 1.31 (-0.02), IMMU: 3.71 (-0.01), PCYC: 134.58 (+0.60), ONCY: 0.84 (unch), PFE: 30.23 (+0.03), LLY: 67.95 (-0.40), BMY: 58.71 (-0.10), GSK: 45.82 (+0.66), JNJ: 108.86 (+0.04), SNTA: 3.34 (+0.23), NVS: 92.66 (+0.03), XLRN: 33.39 (+1.13), ARRY: 3.90 (+0.06), CELGZ: 3.19 (-0.02), EXEL: 1.80 (+0.01)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.22 (-0.17), LLY: 67.95 (-0.40), CNCE: 13.24 (-0.13), OPK: 8.50 (-0.13), AZN: 74.27 (+1.06), ALXN: 194.99 (-0.81), ICPT: 171.32 (-5.03), NPSP: 29.33 (+2.42), XLRN: 33.39 (+1.13)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.01), IMGN: 9.97 (+0.02), AMGN: 162.38 (-0.71), LLY: 67.95 (-0.40), ONTX: 4.90 (+0.04), BMY: 58.71 (-0.10), GSK: 45.82 (+0.66), OXGN: 1.90 (-0.08), XLRN: 33.39 (+1.13), KPTI: 42.50 (-0.18), NVS: 92.66 (+0.03)
Acceleron Pharma's (XLRN) CEO John Knopf on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:29AM CST
XLRN: 33.39 (+1.13)
Acceleron posts 3Q loss
Automated Insights - Fri Nov 07, 7:15AM CST
CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Friday reported a loss of $8 million, or 25 cents per share, in its third quarter.
XLRN: 33.39 (+1.13)
Acceleron Pharma beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:32AM CST
XLRN: 33.39 (+1.13)
Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results
Business Wire - Fri Nov 07, 6:30AM CST
--- Phase 2 data from end-stage renal disease trial to be presented at ASN -
XLRN: 33.39 (+1.13)
Acceleron Announces New Clinical Data Presentations at the 2014 American Society of Hematology Annual Meeting
Business Wire - Thu Nov 06, 8:32AM CST
--Phase 2 data from myelodysplastic syndromes trial selected for oral presentation
XLRN: 33.39 (+1.13)
Acceleron Pharma Is Due For A Market Correction And Is An Attractive Short Candidate During The Coming Months
Clinically Sound Investor - at Seeking Alpha - Fri Oct 31, 7:59AM CDT
XLRN: 33.39 (+1.13)
Acceleron Pharma to Host Third Quarter 2014 Financial Results Conference Call and Webcast on November 7, 2014
Business Wire - Thu Oct 30, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio webcast to report its third quarter 2014 financial results and provide a corporate update on Friday, November 7, 2014, at 9:00 AM EST.
XLRN: 33.39 (+1.13)
Acceleron Pharma to Present at Upcoming Investor Conferences in November
Business Wire - Wed Oct 29, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in several upcoming investor conferences.
XLRN: 33.39 (+1.13)
Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014
Business Wire - Thu Oct 23, 9:52AM CDT
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that its collaboration partner, Celgene, and investigators on the sotatercept program will present preclinical and interim clinical data at the American Society of Nephrology (ASN) Kidney Week 2014. The meeting will be held in Philadelphia on November 11-16, 2014.
XLRN: 33.39 (+1.13)
Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder
Business Wire - Wed Oct 22, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder (CKD-MBD) with Ravi Thadhani, M.D., M.P.H. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept in patients with end-stage renal disease with mineral and bone disorder.
XLRN: 33.39 (+1.13)
A Quick Look at Celgene Corporation's Drug Development Pipeline
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 16, 8:35AM CDT
Source: Dr. Wendy Longo via Flickr . We're taught, as investors, to keep our eyes on the future because the stock market rarely gives much credence to what a business has done in the past. This couldn't be truer when it comes to the...
XLRN: 33.39 (+1.13), CELG: 107.50 (-0.51)
Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083
Business Wire - Tue Oct 14, 6:30AM CDT
-- Fourth internally discovered drug expands Acceleron's clinical pipeline --
XLRN: 33.39 (+1.13)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 86.29 (-1.31), ARQL: 1.19 (+0.02), BMY: 58.71 (-0.10), GSK: 45.82 (+0.66), ONTY: 1.68 (+0.01), ECYT: 6.41 (+0.23), MRK: 59.39 (+0.58), AEZS: 0.61 (-0.01), GALE: 1.94 (+0.01), NVS: 92.63 (unch), XLRN: 33.39 (+1.13), KPTI: 42.50 (-0.18)
Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline
at The Street - Thu Oct 02, 8:21AM CDT
An Acceleron update in December could reignite investor interest in the stock.
BLUE: 42.00 (-0.50), XLRN: 33.39 (+1.13)
Will Acceleron (XLRN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 7:56AM CDT
Will Acceleron (XLRN) Continue to Surge Higher?
XLRN: 33.39 (+1.13)
Acceleron to Host Educational Webcast on Beta-thalassemia
Business Wire - Wed Oct 01, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on beta-thalassemia with Ellis Neufeld, M.D., Ph.D. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept and luspatercept in patients with beta-thalassemia, MDS, and end-stage renal disease with mineral and bone disorder.
XLRN: 33.39 (+1.13)
Acceleron to Webcast Presentation at Leerink Partners Rare Disease Roundtable
Business Wire - Mon Sep 29, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will present a corporate overview at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 10:15 a.m. EDT at Le Parker Meridien Hotel in New York City.
XLRN: 33.39 (+1.13)
